Overview

A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)

Status:
Completed
Trial end date:
2006-01-05
Target enrollment:
Participant gender:
Summary
Study will assess efficacy, safety and tolerability of brivaracetam in post-herpetic neuralgia (PHN). Duration of 7 weeks divided into 3 periods with no up-titration, nor down-titration.
Phase:
Phase 2
Details
Lead Sponsor:
UCB Pharma
Treatments:
Brivaracetam